Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

therapeutics 864 - exam 1 > Kinase inhibitors > Flashcards

Kinase inhibitors Flashcards

1
Q

What is unique about the action of the Tamoxifen as compared to Fluvestrant?

a. It leads to ER degradation
b. It holds ER out of the nucleus
c. It ejects ER from the cell
d. It activates ER in bone

A

d. It activates ER in bone

Fluvestrant degrades ER

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Which of the following is not a hormone responsive cancer type?

a. Breast cancer
b. Ovarian cancer
c. Prostate Cancer
d. Endometrial cancer

A

d. Endometrial cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Which of the following is only used in the postmenopausal setting?

a. Letrozole
b. Tamoxifen
c. Leuprolide
d. Raloxifene

A

a. Letrozole

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Which compound acts directly on AR?

a. Leuprolide
b. Abiraterone
c. Degarelix
d. Enzalutamide

A

d. Enzalutamide

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

signal transduction through _______ drives proliferation in cancer

A

kinases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

kinases work on ________ factors which change genes

A

transcription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

there are __#___ human kinases & more than ___#__ genes encoding potential kinases

There are currently __#__ approved kinase inhibitors all with a diverse structure

A

518; 900

~81

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

kinase inhibitors require _____ to guide their application.

what are the 2 main driver mutations in lung cancer

A

biomarkers

EGFR & KRAS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Diagnostic Molecular pathology:

Genomic ____from lung cancer biopsies are tested via PCR for a particular mutation of _____.
If positive these patients will go on anti-_____ therapies.

A

DNA; EGFR; EGFR

EGFR= epidermal growth factor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

cell signaling is largely driven by the transfer of ___________

A

phosphates

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is the major source of the phosphate group that is transferred by a kinase to a target protein?

A

Adenosine triphosphate (ATP)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

__________ is a common target of several kinases.

______ + __________+ _________ can also be phosphorylated. This leads to dimerization and cascade

A

tyrosine
serine. threonine, lipids

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

______ are prime targets for small molecule inhibitors

A

kinases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

kinases are generally made up of __ and ____ lobes connected by a hinge region.

an _______ loop controls controls access to the active site

A

N & C lobes
activation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Type I inhibitors bind to the ________conformation of the kinase.

Type II inhibitors bind and stabilize the ______conformation of the kinase.

Type III inhibitors occupy an ______pocket outside of the ATP-binding pocket.

A

active

inactive

allosteric

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Competitive Inhibitors bind kinase in a __reversible/irreversible__ fashion and therefore must compete with ATP for binding.

A

reversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

________Inhibitors tend to covalently bind with a reactive nucleophilic _______residue proximal to the ATP-binding site, resulting in the blockage of the ATP site and
_______ inhibition.

A

covalent; cysteine residue; irreversible

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Which amino acid is not a target of phosphorylation?
a. Tyrosine
b. Serine
c. Threonine
d. Alanine

A

d. Alanine

only has a methyl group

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the source of the phosphate the gets transferred onto a substrate by a kinase?
a. SAM
b. DNA
c. RNA
d. ATP

A

d. ATP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

EGFR targeted kinase inhibitors

-Mutations in EGFR cause the receptor to be constitutively ___inactivated/activated___.
-Patients with these mutations show an enhanced response to EGFR inhibitors.

A

activated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what is the main Type 1 (EGFR) targeted kinase inhibitor? what type of cancer is it used to treat

A

Gefitinib
>largely being replaced by more favorable covalent inhibitors (Afatinib and Neratinib)

EGFR-mutant metastatic NSCLC

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Gefitinib (IRESSA - EGFR kinase inhibitor)

> EGFR signaling induces cell proliferation

> EGFR is __under/over___expressed and has higher signaling activity in __%___ of human cancers

> EGFR overexpression correlates with poor prognosis

> Erlotinib is a small molecule __reversible/irreversible__inhibitor of EGFR tyrosine kinase
-Competitively inhibits the enzyme by binding to the ____ binding site in the kinase domain
-Inhibition of kinase activity turns off signal to proliferate

> Gefitinib and Erlotinib are approved for treatment of patients with __________ cancer whose tumors have EGFR exon ____ or _____mutations.

> Drugs are well tolerated – most adverse effects (fatigue, rash, diarrhea).

A

over; 25-50%

reversible; ATP

metastatic non-small cell lung cancer (NSCLC)

19 or exon 21 (L858R)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

afatinib (gilotrif) is a _________ inhibitor of all ___ receptors

tx of _____________ cancer with EGFR mutations

A

covalent; ErbB

EGFR mutant Non-small cell lung cancer (NSCLC)

> Dacomitinib also a covalent inhibitor approved for non-resistant EGFR mutant lung cancer.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

t/f EGFR inhibitor-associated skin rash is normal

A

true, it means it’s working and pt is more likely to respond to inhibitor

NEED TO KNOW THIS SIDE EFFECT
EGFR inhibitors = RASH

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

_____ causes resistancce to Geftinib.

______ is used in pts with this mutation

A

Osimertinib

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

Osimertinib is a _____ generation EGFR inhibitor. It is a ________ kinase inhibitor.

new reports of ______mutation that abrogates binding –> osimertinib no longer effective

A

third; covalent; C797

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

Are EGFR inhibitors curative?

A

no, pt will be taking them forever

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

EGFR (ErbB1) forms _______ with HER2 (ErbB2).

A

heterodimer

29
Q

_____ is amplified in breast cancer

A

HER2

30
Q

Lapatinib (Tykerb):

Small molecule tyrosine kinase inhibitor that blocks HER2 and EGFR signaling

Selective for the treatment of ______ breast cancer

Currently approved (in combination with _________) for the treatment of advanced __non metastatic/metastatic____ breast cancer in patients who have progressed on other therapies

A __________inhibitor of both EGFR and HER2

Common side effects include diarrhea, nausea and vomiting

Reversible decrease in cardiac function – watch for symptoms of _______________

A

HER2+

capecitabine

metastatic

reversible

congestive heart failure (CHF)

31
Q

neratinib, dacomitinib & afatinib are are similar to _______but have different indications

A

lapatinib

32
Q

Tucatinib (tukysa)

Small molecule tyrosine kinase inhibitor that preferentially binds ____

Selective for the treatment of _____ breast cancer

Currently approved as a ______line therapy (in combination with ______ and _________) for the treatment of advanced metastatic breast cancer in patients who have progressed on other therapies.

Adverse recations appear to be __increased/reduced___compared to lapatinib or the covalent pan-ErbB inhibitors. Potentially due to increased specificity for HER2.

A

HER2

HER2+

second line

trastuzumab and capecitabine

reduced

33
Q

Which compounds inhibit EGFR?

a. Gefitinib
b. Osmertinib
c. Afatinib
d. Lapatinib
e. All of the above

A

e. All of the above

34
Q

What mutation in EGFR confers resistance to 1st and 2nd generation EGFR inhibitors?

a. L858R
b. Exon 19 deletion
c. Exon 14 deletion
d. T790M

what drug was made as a 3rd generation to target this?

A

d. T790M

osimertinib

35
Q

______ mutations are found in 30% of acute myeloid leukemia either in internal tandem duplication (ITD-more common) or activating mutation in the tk domain (less common)

a. L858R
b. Exon 19 deletion
c. Exon 14 deletion
d. T790M
e. FLT3

A

e. FLT3

increases dimerization of receptors which activate the kinase. NOT a point mutation like EGFR inhibitors

36
Q

The _______ ligand is a cytokine receptor important for hematopoietic cell survival & proliferation

A

FLT3

37
Q

First generation FLT3 inhibitors are broad kinase inhibitors –> ___drug name______

Second generation FLT3 inhibitors are more specific –> __drug name__

Type II inhibitors are specific for ITD mutations (30% of AML) –> __drug name__

A

midostaurin (type I)

crenolanib (type I)

Quizartinib (type II)

38
Q

Quizartinib is specific for what kind kind of mutations

A

ITD mutations

Quizartinib is a type II inhibitor (FLT3 inhibitors)

39
Q

which generation of FLT3 inhibitors are more toxic?

A

1st gen –> midostaurin

40
Q

t/f Vascular Endothelial Growth Factor Receptor (VEGFR) is driven by molecular diagnostics

A

false; not driven by molecular diagnostics

41
Q

t/f Capmatinib is a MET inhibitor

A

true

42
Q

Chromosomal Translocations:

Philadelphia chromosome (Ph1) is the prototype chromosomal translocation

Formed by joining the 5’-portion of the Bcr gene (chromosome _#__) with the 3’-portion of the Abl gene (chromosome __#__)

A chimeric transcript is produced, called Bcr-Abl

Chimeric gene is transcribed into a novel 8.5 kb ______

RNA translated into a unique 210 kD protein not found in normal cells

The Ph1 chromosome is demonstrable in ~____% of chronic myeloid leukemia

A

22

9

mRNA

95

43
Q

philadelphia chromosome is demonstrable is what kind of cancer?

A

chronic myeloid leukemia

44
Q

why is the chimeric transcript that is produced by philadelphia chromosome translocation, Bcr-Abl, so bad?

A

drives proliferation in several pathways

the chimeric protein is constitutively active which results in malignancy

45
Q

t/f Abl protein is a tyrosine kinase

A

true

46
Q

What does imatinib (Gleevec) target?

A

Abl tyrosine kinase inhibition

47
Q

Imatinib (Gleevec) is a Type ___ small molecule inhibitor of the Abl tyrosine kinase

Inhibition of the Abl tyrosine kinase results in both reduced proliferation and enhanced apoptotic cell death in __cancer__ and ___cancer___

Primary indication is in the treatment of _____cancer___

Toxicities:
-Nausea and vomiting common
-Fluid retention and edema
-Neutropenia and thrombocytopenia frequent but mild

A

type II

CML and GIST

chronic myeloid leukemia (CML)

48
Q

do pts take imatinib and other abl inhibitors short term or long term

A

long term - for life

resistance is a lifelong battle!

49
Q

what does ponatinib (iclusig) inhibit? What specifc gatekeeper mutation does it inhibit?

A

BCR-Abl

mutation T315I that is resistant to all other BCR-Abl compounds

50
Q

___________ translocation is a significant driver event in lung cancer (6% of NSCLC)

A

EML 4-ALK

wild type ALK is a transmembrane receptor tk similar to EGFR that fuses w ELM4 causing it to become active

51
Q

Alectinib

More specific inhibitor of _____

Requires a ______diagnostic test for the ______ gene

Indicated for the treatment of patients with ______-positive, metastatic non-small cell lung cancer (NSCLC) who have progressed on or are intolerant to ________. This indication is approved under accelerated approval based on tumor response rate and duration of response.

Brigatinib also recently approved NSCLC that have ALK mutations.

A

ALK-anaplastic lymphoma kinase

companion, fusion

anaplastic lymphoma kinase (ALK)

crizotinib

52
Q

most melanomas have ______ mutations which activates kinase pathways & self proliferation

A

Braf

53
Q

DabRAFenib is a __________ generation BRAF-600 inhibitor for tx of BRAF V600E/K mutatnt metastatic melanoma

used in combo with _________

__________ cancer commonly has Ras & BRAF-V600 mutations by they do not respond to DabRAFenib.

Can be used in NSCLC patients that are ___+ or -____ for BRAF-600 mutations

A

second

tramatenib

colorectal

+

54
Q

Trametinib inhibits the kinase activity of _____ and ____

it is a type ____ _____ kinase inhibitor

it is not indicated for tx of pts who have received prior ____ inhibitor therapy

what side effects are common?

A

MEK1 and MEK2

III allosteric

BRAF

rash, diarrhea, lymphedema

55
Q

Bruton’s Tyrosine Kinase (BTK) is importnat for normal __ cell activity & ___ cell tumor growth

ibrutinib is a _______ inhibitor of BTK

A

B cell

covalent

56
Q

BTK (Bruton’s tyrosine kinase) inhibitors are primarily used in ____ and ___

A

MCL & CLL (B cell cancers)

57
Q

_________ is a 2nd gen covalent BTK inhibitor that is more potent & selective than 1st gen, ibrutinib & is also indicated for B-cell lymphoma (MCL & CLL)

A

acalaBRUTinib

58
Q

Rapamycin is also known as ________. Rapamycin analogues inhibit the function of ________. It also inhibits immune response by blocking ______ signal transduction

A

sirolimus; mammalian target of rapamycin (mTOR); IL-1

59
Q

mTOR is a ______-________ kinase

A

serine-threonine

60
Q

Sirolimus & Everolimus only inhibit ______ and not mTORC2 which can lead to feedback activation of ____

A

mTORC1; akt

61
Q

_________ is a major problem with kinase inhibitors. However, the main goal kinase inhibitors is the decrease the use of toxic ________

A

resistance; chemotherapies

62
Q

Genomic DNA from lung cancer biopsies are tested via PCR for particular mutation of EGFR, if + pts go on anti-EGFR therapies. This is an example of __diagnostic or prognostic___ molecular pathology

A

diagnostic

63
Q

t/f oncotype dx helps predict recurrence & therefore can prevent over tx and can drive indications for specific therapies

A

false; CAN NOT drive indications for specific therapies

can only predict how a pt may respond to tx and help determine why some pts develop metastasis over others

64
Q

Which of the following drugs targets Her2?

a. Sirolimus
b. Alectinib
c. Vemurafinib
d. Tucatinib

A

d. Tucatinib

65
Q

Which of the following drugs targets a kinase that is produced by formation of the Philadelphia chromosome?

a. Alectinib
b. Gefitinib
c. Imatinib
d. binimetinib

A

c. Imatinib

66
Q

Which compound below is not a covalent kinase inhibitor?

	A. Gefitinib
	B. Osimertinib 
	C. Afatinib 
	D. Acalabrutinib
A

A. Gefitinib

67
Q

Which type of kinase inhibitor can bind in the ATP binding site and stabilize the inactive confirmation of a kinase?

	A. Type I
	B. Type II 
	C. Type III
	D. Type IV
A

B. Type II

68
Q

A CML patient initially tested positive for the Philadelphia chromosome and has enjoyed a 5-year response to imatinib. Unfortunately, the disease has recurred and now tests positive for a T315I mutation.

> Describe how T315I prevents the efficacy of imatinib? (1 sentence)

> What might the next course of BCR-Abl-targeted therapy might include?

A

resistance occurs overtime, & it prevents imatinib from binding to Bcr-Abl

Ponatinib

therapeutics 864 - exam 1 (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions